Engitix Therapeutics logo

Engitix Therapeutics

Decoding the ECM space to unlock unprecedented therapies for chronic diseases

63 employees · est. 2016 · London, United Kingdom

VS
HemoShear Therapeutics logo

HemoShear Therapeutics

Developing new treatments for rare metabolic disorders

27 employees · est. 2008 · Charlottesville, United Stat...

HemoShear Therapeutics is the older company (2016 vs 2008); Engitix Therapeutics is the larger of the two.

Side-by-Side Comparison

Engitix Therapeutics HemoShear Therapeutics
Founded
2016 2008 older
Headquarters
London, United Kingdom Charlottesville, United States
Employees
63 larger 27
Industry
Biotechnology, Health Care, Life Sciences Biotechnology, Health Care
Funding Stage
Series A Debt Financing
Total Funding
$59.00M $54.95M
Funding Rounds
2 8
Services
ECM Platform Development, Disease Modeling, Therapeutic Discovery, Research Collaborations Not tracked yet
Target Customers
Pharmaceutical Companies, Biotech Firms, Medical Researchers, Healthcare Providers Not tracked yet
Taxonomy
Human Extracellular Matrix, Discovery Platform, Fibrosis Therapeutics, Solid Tumor Therapy, In Vitro Models, Drug Target Identification, Biomarker Discovery, Mechanism Of Action Study, Liver Disease Research, Regenerative Medicine, Drug Profiling, Bioartificial Liver Devices, Organ Decellularisation, Tissue Engineering, 3D Spheroids Drug Discovery, Metabolic Disorders, Rare Diseases, Human Disease Models, Tissue Engineering, Pharmaceutical Partnerships, Clinical Success, Genetic Defects, Liver Diseases, Treatment Development
Website
engitix.com hemoshear.com
Engitix Therapeutics logo

About Engitix Therapeutics

Engitix Therapeutics, founded in 2016 and headquartered in the United Kingdom, is at the forefront of the Biotechnology, Health Care, and Life Sciences industries. The company aims to transform therapy development for chronic diseases through its pioneering extracellular matrix (ECM)-based discovery...

HemoShear Therapeutics logo

About HemoShear Therapeutics

HemoShear Therapeutics is a biotechnology company with a focus on developing new treatments for rare metabolic disorders. Established in 2008, the company utilizes a proprietary technology that allows them to recapitulate diseases using tissue from livers of children born with genetic defects. This...

We will tell you when either one moves

BounceWatch watches Engitix Therapeutics and HemoShear Therapeutics for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at Engitix Therapeutics and HemoShear Therapeutics — by email.

Frequently Asked Questions

Engitix Therapeutics — Decoding the ECM space to unlock unprecedented therapies for chronic diseases. HemoShear Therapeutics — Developing new treatments for rare metabolic disorders. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
Engitix Therapeutics has raised $59.00M while HemoShear Therapeutics has raised $54.95M.
Engitix Therapeutics and HemoShear Therapeutics operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare Engitix Therapeutics with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at Engitix Therapeutics on 29 Apr 2026, and HemoShear Therapeutics on 12 Sep 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy